JP2002509104A5 - - Google Patents

Download PDF

Info

Publication number
JP2002509104A5
JP2002509104A5 JP2000539837A JP2000539837A JP2002509104A5 JP 2002509104 A5 JP2002509104 A5 JP 2002509104A5 JP 2000539837 A JP2000539837 A JP 2000539837A JP 2000539837 A JP2000539837 A JP 2000539837A JP 2002509104 A5 JP2002509104 A5 JP 2002509104A5
Authority
JP
Japan
Prior art keywords
composition
magnesium
pills
memantine
dextromethorphan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000539837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002509104A (ja
JP4562911B2 (ja
Filing date
Publication date
Priority claimed from US09/006,641 external-priority patent/US5952389A/en
Priority claimed from US09/193,892 external-priority patent/US6294583B1/en
Priority claimed from US09/224,829 external-priority patent/US6057373A/en
Application filed filed Critical
Priority claimed from PCT/US1999/000144 external-priority patent/WO1999036064A2/en
Publication of JP2002509104A publication Critical patent/JP2002509104A/ja
Publication of JP2002509104A5 publication Critical patent/JP2002509104A5/ja
Application granted granted Critical
Publication of JP4562911B2 publication Critical patent/JP4562911B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000539837A 1998-01-13 1999-01-13 遅発性ジスキネジア及び他の運動障害の治療方法 Expired - Lifetime JP4562911B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/006,641 1998-01-13
US09/006,641 US5952389A (en) 1998-01-13 1998-01-13 Methods of treating tardive dyskinesia and other movement disorders
US09/193,892 US6294583B1 (en) 1998-01-13 1998-11-18 Methods of treating tardive dyskinesia and other movement disorders
US09/193,892 1998-11-18
US09/224,829 1999-01-04
US09/224,829 US6057373A (en) 1997-05-22 1999-01-04 Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
PCT/US1999/000144 WO1999036064A2 (en) 1998-01-13 1999-01-13 Methods of treating tardive dyskinesia and other movement disorders

Publications (3)

Publication Number Publication Date
JP2002509104A JP2002509104A (ja) 2002-03-26
JP2002509104A5 true JP2002509104A5 (cg-RX-API-DMAC7.html) 2006-03-09
JP4562911B2 JP4562911B2 (ja) 2010-10-13

Family

ID=27358163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000539837A Expired - Lifetime JP4562911B2 (ja) 1998-01-13 1999-01-13 遅発性ジスキネジア及び他の運動障害の治療方法

Country Status (6)

Country Link
EP (1) EP1047436B1 (cg-RX-API-DMAC7.html)
JP (1) JP4562911B2 (cg-RX-API-DMAC7.html)
CN (1) CN1293573A (cg-RX-API-DMAC7.html)
AU (1) AU765522B2 (cg-RX-API-DMAC7.html)
CA (1) CA2318095C (cg-RX-API-DMAC7.html)
WO (1) WO1999036064A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
WO2001008670A2 (en) * 1999-07-29 2001-02-08 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
US20050192220A1 (en) * 2001-02-05 2005-09-01 Gevys Pharmaceuticas Ltd. Composition and method for potentiating drugs
AUPR625901A0 (en) * 2001-07-10 2001-08-02 Mcgregor, Neil A method for treatment and/or prophylaxis
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US7456224B2 (en) 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
WO2005110412A1 (en) * 2004-05-14 2005-11-24 Green Cross Corp. Neuroprotective properties of dextrorotatory morphinans
US20060079582A1 (en) * 2004-09-23 2006-04-13 Jeffrey Jonas Memantine for the treatment of childhood behavioral disorders
AU2005309601A1 (en) * 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject
EP1928445A1 (en) * 2005-09-16 2008-06-11 Cereuscience AB Method and means of preventing and treating sleep disordered breathing
SI2089417T1 (sl) 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
AU2012345659B2 (en) 2011-12-02 2017-09-28 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
HUE039750T2 (hu) * 2014-06-26 2019-02-28 Contera Pharma Aps Hidroxi-buspiron mozgászavarok kezelésére
CN104188970A (zh) * 2014-08-26 2014-12-10 上海交通大学医学院附属新华医院 右美沙芬在治疗眼睑痉挛或梅杰综合征中的应用
WO2017044491A1 (en) * 2015-09-08 2017-03-16 The Children's Hospital Of Philadelphia Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome
CN110430883A (zh) * 2017-02-10 2019-11-08 阿沙里那制药公司 用于医学治疗的3β-羟基-5α-孕烷-20-酮
CN111902138A (zh) * 2018-01-29 2020-11-06 法奈克斯公司 在乙酰胆碱酯酶抑制剂治疗失去反应的患者中对阿兹海默氏病的基于巴氯芬和阿坎酸的治疗
WO2020229443A1 (fr) 2019-05-16 2020-11-19 Synapharm Industrial Synthesis Composé et composition pour utilisation dans le traitement du syndrome prémenstruel et/ou du trouble dysphorique prémenstruel
CN115184501A (zh) * 2022-07-20 2022-10-14 中国医学科学院病原生物学研究所 血清代谢物组合筛查在诊断肌张力障碍症中的应用
WO2025167857A1 (zh) * 2024-02-06 2025-08-14 南京纽邦生物科技有限公司 用于增强或改善肌肉功能和/或提高运动表现和/或预防或缓解疲劳的方法和组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2457281A1 (fr) * 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
US4985256A (en) * 1988-04-27 1991-01-15 Bionix Corporation Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory loss or improving impairment of memory
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US5356902A (en) * 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5470978A (en) * 1992-11-18 1995-11-28 Eli Lilly And Company Process and intermediates for the preparation of excitatory amino acid receptor antagonists
MX9701477A (es) * 1994-09-02 1998-02-28 Univ Virginia Commonwealth Composicion para aliviar el dolor, que contiene un analgesico no narcotico y un mejorador de analgesia.
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists

Similar Documents

Publication Publication Date Title
EP0660707B1 (en) Amantadine and related compounds for use in the treatment of peripheral neuropathy
DE69733081T2 (de) Antikonvulsive mitteln enthaltende zubereitung zur behandlung von neuropathischen schmerzen
NZ220631A (en) Pharmaceutical composition containing levodopa methyl ester
US20030064122A1 (en) Abuse resistant pharmaceutical composition containing capsaicin
CA2126611A1 (en) Opiod Formulations Having Extended Controlled Release
JP2002539245A5 (cg-RX-API-DMAC7.html)
ATE322892T1 (de) Stabilisierte tramadol formulierungen mit verzögerter freisetzung
CA2318095A1 (en) Methods of treating tardive dyskinesia and other movement disorders
MEP48308A (en) Tamper-resistant oral opioid agonist formulations
AU3357800A (en) Method of preparing alkylated salicylamides
AU2002309885A1 (en) Abuse resistant pharmaceutical composition containing capsaicin
BR9810403A (pt) Sais da sertralina e formas de dosagem de liberação sustentada da sertralina
AR032730A1 (es) Desnaturalizantes para las sales aminas simpaticomimeticas
SK14282000A3 (sk) Farmaceutický prostriedok na liečenie závislosti od alkoholu a drog obsahujúci opiátového antagonistu a modulátor súhrnu nmda receptorov
TR200103613T2 (tr) Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler.
BR9916361A (pt) Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
US20120064152A1 (en) Analgesic and Anti-Inflammatory Compositions Comprising Domperidone and Methods of Using Same
JPH01268633A (ja) Ｌ−ドーパの直腸被吸収性形態
ZA200105040B (en) Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient.
UA76753C2 (uk) Комбінація галантаміну або дезоксипеганіну та протизбуджувального агента, її застосування (варіанти) для лікування наркотичної або токсичної залежності
ATE253354T1 (de) Kapseln mit loratadin und pseudoephedrin enthaltenden zusammensetzungen
RU99119233A (ru) Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени
BRPI0413883A (pt) composição e método para a administração de um composto farmacologicamente ativo a um mamìfero
Harris et al. Mechanisms and treatment of cytotoxic-induced nausea and vomiting
IE841048L (en) Anti-seizure medicaments